Evatanepag

Evatanepag (CP-533536) is a non-prostanoid, potent and selective EP2 receptor agonist. Evatanepag can induce local bone formation in vivo. Evatanepag can be used in the research of fractures, bone defects, asthma[1][2].

Product Specifications

CAS Number

[223488-57-1]

Product Name Alternative

CP-533536 free acid

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Endocrinology; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Evatanepag.html

Purity

99.78

Solubility

DMSO : ≥ 32 mg/mL

Smiles

CC(C)(C)C(C=C1)=CC=C1CN(S(C2=CN=CC=C2)(=O)=O)CC3=CC(OCC(O)=O)=CC=C3

Molecular Formula

C25H28N2O5S

Molecular Weight

468.57

Precautions

H302, H315, H319, H335

References & Citations

[1]Cameron KO, et al. Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation. Bioorg Med Chem Lett. 2009 Apr 1;19 (7) :2075-8.|[2]Judith Plaza, et al. In Vitro and In Vivo Validation of EP2-Receptor Agonism to Selectively Achieve Inhibition of Mast Cell Activity. Allergy Asthma Immunol Res. 2020 Jul;12 (4) :712-728. |[3]V M Paralkar, et al. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci U S A. 2003 May 27;100 (11) :6736-40.